公开(公告)号：AU2020202752B2

公开(公告)日：2022-04-07

申请号：AU2020202752

申请日：2020-04-24

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：AU2018204179A1

公开(公告)日：2018-07-05

申请号：AU2018204179

申请日：2018-06-12

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：SG10201702913XA

公开(公告)日：2017-06-29

申请号：SG10201702913X

申请日：2012-10-19

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J

Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：CR20160203A

公开(公告)日：2016-08-31

申请号：CR20160203

申请日：2014-09-29

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  CHEN WEI ,  WANG LONGCHENG ,  JIA ZHAOZHONG J

IPC: A61P19/02 ,  A61P19/00 ,  C07D401/14 ,  C07D403/14

Abstract: En la presente se describen compuestos que forman enlaces 15 covalentes con la tirosina cinasa de Bruton (Btk). También se describen inhibidores irreversibles de Btk. Además, también se describen los inhibidores reversibes de Btk. También se describen composiciones farmacéuticas que incluyen los compuestos. Se describen métodos para usar inhibidores de Btk, 20 solos o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades afecciones autoinmunitarias, enfermedades afecciones heteroinmunitarias, cáncer, inclusive linfoma y enfermedades afecciones inflamatorias.

公开(公告)号：NZ702485A

公开(公告)日：2016-04-29

申请号：NZ70248511

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK D ,  FYFE GWEN ,  BUGGY JOSEPH J

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Disclosed is the use of the inhibitor of Bruton’s tyrosine kinase (Btk) (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one / ibrutinib / PCI-32765 in the preparation of a medicament for treating Waldenstrom’s macroglobulinemia in an individual wherein, the medicament comprises from 420mg to 840mg of said inhibitor, the medicament is formulated for oral administration, and said individual has already received at least one prior therapy for Waldenstrom’s macroglobulinemia.

公开(公告)号：AU2010306921C1

公开(公告)日：2016-03-17

申请号：AU2010306921

申请日：2010-10-12

Applicant: PHARMACYCLICS LLC

Inventor： CHEN WEI ,  LOURY DAVID J ,  MODY TARAK D ,  VERNER ERIK ,  SMYTH MARK STEPHEN ,  LUO WENCHEN

IPC: C07D401/04 ,  A61K31/519 ,  A61P19/02 ,  A61P19/10 ,  C07D401/14 ,  C07D487/04

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

公开(公告)号：MX387728B

公开(公告)日：2025-03-18

申请号：MX2020004501

申请日：2012-12-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/437 ,  A61P35/00

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：MX380504B

公开(公告)日：2025-03-12

申请号：MX2016012396

申请日：2012-12-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61K31/519 ,  A61P35/02

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：AU2018201203A1

公开(公告)日：2018-03-08

申请号：AU2018201203

申请日：2018-02-20

Applicant: PHARMACYCLICS LLC

Inventor： CHEN WEI ,  LOURY DAVID J ,  YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN

IPC: C07D473/32 ,  A61K31/52 ,  A61P35/00 ,  A61P37/00

Abstract: Abstract Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：AU2017272271A1

公开(公告)日：2018-01-04

申请号：AU2017272271

申请日：2017-12-07

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.